Amgen Inc (AMGN) scored on five pillars from its reported financial statements, and ranked against 212 Healthcare companies.
Amgen Inc (AMGN) scores 5.9 out of 10 as of , computed from its reported financial statements. That reads as solid quality. The reading rests on profitability, and solvency is what holds it back.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
Amgen Inc’s returns on capital beat their cost in almost every measured year, by a clear margin: 4 of 5 indicators passed.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
The Quality Score for AMGN stands at 5.9 out of 10 as of October 19, 2026, which puts Amgen Inc in the solid quality band. This band covers companies that do several things well but not everything, so the pillar detail below matters more than the headline. It rolls Amgen Inc’s profitability, solvency, growth, efficiency and predictability into one number, each judged against the norms of its sector.
Ranked with the 212 Healthcare companies Lemma publishes, the score sits at the 72nd percentile, above the middle of the group. For reference, the middle of the group scores 4.4 and a company needs 6.0 to reach its top quarter, which leaves Amgen Inc well above the median.
On profitability, Amgen Inc scores 8.5, a strong reading. Its peers have a median of 2.7 across 210 Healthcare companies, which places it well above them, at the 92nd percentile. High profitability means each unit of capital and of sales is turning into more profit than at most of its peers, which is usually the first sign of pricing power or a cost advantage.
Solvency scores 4.3 out of 10, which reads as average. The median across 150 Healthcare companies is 6.5, so Amgen Inc is well below its peers on this pillar and ranks at the 20th percentile. Middling solvency says the balance sheet is neither a strength nor a constraint today.
On growth, Amgen Inc scores 4.9, an average reading. Its peers have a median of 4.9 across 107 Healthcare companies, which places it in line with them, at the 51st percentile. Average growth reflects a business expanding at roughly the pace of its sector, without a clear acceleration or decline.
On efficiency, Amgen Inc scores 5.3, an average reading. Its peers have a median of 6.0 across 200 Healthcare companies, which places it below them, at the 35th percentile. Middling efficiency is unremarkable on its own, though improvements here tend to show up in free cash flow first.
On predictability, Amgen Inc scores 5.6, an average reading. Its peers have a median of 3.4 across 207 Healthcare companies, which places it well above them, at the 76th percentile. Middling predictability suggests some volatility in the record, enough to read the other pillars with a little caution.
The gap between Amgen Inc’s best and worst pillar is wide: profitability at 8.5 against solvency at 4.3, 4.2 points apart. An average of two readings this different deserves a closer look than the headline number. A profitability lead usually reflects something durable in the business model rather than a good year. When solvency is the soft spot, the question is how much of the cash flow is already spoken for by debt.
The pillar with the most room to move the score is solvency. If it rose to the median of Healthcare companies, 6.5, Amgen Inc’s overall score would go from 5.9 to about 6.3. The weights add up to 100 points (profitability 25, solvency 20, growth 20, efficiency 15, predictability 20), and Amgen Inc has a reading on every pillar.
For a fair comparison, start with companies of a similar size: the Healthcare companies below are nearest to Amgen Inc by market value, each scored on the same pillars.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Amgen Inc scores 5.9 out of 10, which reads as solid quality. Its strongest pillar is profitability, its weakest is solvency. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Amgen Inc ranks at the 72nd percentile of the 212 Healthcare companies Lemma publishes a score for. The median there is 4.4 and the top quarter starts at 6.0, against Amgen Inc’s 5.9.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 19, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for AMGN are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card